Clinical Trial Update: ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) [Phase 3]

View source ↗

Summary

Phase 3 trial update for ADS-5102 (amantadine) in levodopa-induced dyskinesia shows completed study with posted results in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesia
• Levodopa-induced Dyskinesia
• Parkinson Disease

Drugs mentioned

• ADS-5102 (amantadine)

Snippet

Sponsor: Adamas Pharmaceuticals, Inc. | Conditions: Dyskinesia, Levodopa Induced Dyskinesia (LID) | Phase 3 | Status: COMPLETED | Results posted: 2018-02-06